Massachusetts-based Surface Oncology will pause the development of its CD39-targeted antibody SRF617 and cut around 20% of its workforce to focus on its lead anti-IL-27 program SRF388, the company announced Wednesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,